- Articles -

The mycoplasma detection market is registering a very healthy growth rate in the past few years. Various factors increasing technological advancements, R&D activities by biopharmaceutical companies, increased government initiatives, increasing demand for fast, accurate, and affordable testing, and the increasing cell culture contamination are driving the mycoplasma detection market. With constantly evolving contamination detection techniques, adoption of biopharmaceuticals in healthcare, and many more key innovations happening across the market are resulting in the market.

Below mentioned are some of the key innovations in mycoplasma detection.

PCR-based Mycoplasma Detection Technique

The PCR-based Mycoplasma Detection Technique is one of the key innovations in the mycoplasma detection market. This technique is affordable and less time-consuming as compared to the traditional costly time-consuming tests.

The mycoplasma detection is performed at different stages of manufacturing and in the elimination of faulty batches. This process can take up to 4 weeks if the mycoplasma detection process is traditionally performed. Using advanced technologies, the time consumed can be reduced to a very great extent.

For instance, MycoSEQ Mycoplasma Detection Kit is a real-time PCR assay designed to detect more than 90 mycoplasma species within 5 hours. In addition to this, the LookOut® Mycoplasma PCR Detection Kit can be used for the highest sensitivity in the detection of Mycoplasma, Acholeplasma, and Ureaplasma contamination in cell cultures.

Cost-Effective Detection Kits

With the advent of technology, the manufacturers are strategically working towards the development of cost-effective mycoplasma detection kits and systems. This furthers enhances the product adoption. The biological industries launched EZ-PCR™ Mycoplasma Detection Kit is highly sensitive, easy to use, easy to run, and easy to interpret.

The kit is cost-efficient and contains a ready-to-use PCR reaction mix. The detection process collects samples in as little as 10 minutes and results are generated within just a few hours. There is vast scope for manufacturers offering cost-effective detection kits and improving their growth.

Testing of Biopharmaceutical Products

The biopharmaceutical industry experiences mycoplasma as the most common contaminant. This is why the industry demands highly effective mycoplasma detection devices. This is creating several opportunities for mycoplasma detection kits manufacturers.

For instance, bioMérieux announced the launch of BIOFIRE® MYCOPLASMA, an innovative test for mycoplasma detection in pharmaceutical products. BIOFIRE® MYCOPLASMA is a very easy-to-use molecular biology test and an innovative creation. DNA extraction, amplification, and detection steps are fully automated in the test and offer the ease of performing the test outside of the laboratory by nearly anyone after simple training.